Belpointe Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Belpointe Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,946	Closed	-$264K	–	1028
2024 Q4	$264K	Buy	1,946 +36	+2%	+$4.41K	0.02%	704
2024 Q3	$239K	Buy	1,910 +19	+1%	+$2.63K	0.01%	740
2024 Q2	$299K	Sell	1,891 -48	-2%	-$6.17K	0.02%	588
2024 Q1	$251K	Buy	+1,939	New	+$238K	0.02%	666
2023 Q2	–	Sell	-1,251	Closed	-$172K	–	3009
2023 Q1	$172K	Sell	1,251 -40	-3%	-$5.19K	0.01%	1009
2022 Q4	$167K	Buy	1,291 +122	+10%	+$14.1K	0.01%	968
2022 Q3	$129K	Buy	+1,169	New	+$118K	0.01%	1032
2021 Q4	–	Sell	-1,810	Closed	-$167K	–	1246
2021 Q3	$167K	Buy	1,810 +250	+16%	+$19.3K	0.01%	934
2021 Q2	$121K	Buy	+1,560	New	+$118K	0.01%	1049

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Belpointe Asset Management's SRPT Position: Q1 2025 in Review

Belpointe Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 1,946 shares — an estimated $264K sold.

Belpointe Asset Management first reported a position in SRPT in Q2 2021 and held it in 9 quarters. The position peaked at $299K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Belpointe Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Belpointe Asset Management sold 1,946 Sarepta Therapeutics shares in Q1 2025, an estimated $264K.
Belpointe Asset Management first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 9 quarters.
Belpointe Asset Management's Sarepta Therapeutics position peaked at $299K in Q2 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Belpointe Asset Management's 13F filing for Q1 2025, filed 20 May 2025.